

**IN THE UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF INDIANA**

ELI LILLY AND COMPANY,	)	
	)	
Plaintiff,	)	
	)	
v.	)	Civil Action No. 1:10 cv-1376 TWP-DKL
	)	
TEVA PARENTERAL MEDICINES, INC.,	)	
APP PHARMACEUTICALS, LLC,	)	
PLIVA HRVATSKA D.O.O.,	)	
TEVA PHARMACEUTICALS USA, INC., and	)	
BARR LABORATORIES, INC.,	)	
	)	
Defendants.	)	
<hr style="border: 0.5px solid black;"/>		

**AMENDED JOINT CLAIM CONSTRUCTION STATEMENT**

Pursuant to the Court’s April 12, 2012, Entry in Preparation for *Markman* Hearing (ECF No. 109), Plaintiff Eli Lilly and Company (“Lilly”) and Defendants Teva Parenteral Medicines, Inc., APP Pharmaceuticals, LLC, Pliva Hrvatska d.o.o., Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. (collectively “Defendants”) hereby submit the following Amended Joint Claim Construction Statement.

(a) The parties have exchanged lists of the claim terms, phrases, or clauses which they believe require construction, as well as proposed constructions. The parties have agreed upon the following constructions:

Claim Term/Phrase	Construction
“an effective amount of folic acid and an effective amount of a methylmalonic acid lowering agent”	“amounts of folic acid and a methylmalonic acid lowering agent that are capable of reducing the prevalence or severity of one or more toxicities associated with the administration of pemetrexed disodium”

“methylmalonic acid lowering agent”	“an agent such as vitamin B12 which can be used to lower the concentration of methylmalonic acid in a mammal”
“an effective amount of pemetrexed disodium”	“an amount of pemetrexed disodium that is capable of providing a therapeutic benefit to the patient in need thereof”

The parties have also agreed that the preambles of claims 1 and 12 are limiting.

(b) The following chart reflects Plaintiff’s and Defendants’ proposed constructions for the claim terms, phrases, or clauses identified by one or more of the parties as requiring construction:

<b>Claim Term/Phrase</b>	<b>Plaintiff’s Proposed Construction</b>	<b>Defendants’ Proposed Construction</b>
“patient”	“patient (i.e., a human under medical care)”	“mammal”
“vitamin B12”	“vitamin B12 (i.e., cyanocobalamin)”	Indefinite

(c) The parties anticipate that less than one day will be needed for the *Markman* hearing.

(d) The parties will not call any witnesses at the *Markman* hearing.

(e) The parties will first address the “patient” claim term (with a background introduction) and then will address the “vitamin B12” claim term, with Plaintiff going first for each issue.

Respectfully submitted,

/s/ Jan M. Carroll

Jan M. Carroll, No. 4187-49  
BARNES & THORNBURG LLP  
11 South Meridian Street  
Indianapolis, Indiana 46204  
(317) 236-1313  
jan.carroll@btlaw.com

OF COUNSEL:

Bruce R. Genderson  
Adam L. Perlman  
Ellen E. Oberwetter  
Dov P. Grossman  
David M. Krinsky  
Megan A. Hughes  
WILLIAMS & CONNOLLY LLP  
725 Twelfth Street, N.W.  
Washington, DC 20005  
(202) 434-5000 (telephone)  
(202) 434-5029 (facsimile)

*Attorneys for Plaintiff  
Eli Lilly and Company*

/s/ Kandi Kilkelly Hidde (w/permission)

David O. Tittle, # 857-49  
Kandi Kilkelly Hidde, #18033-49  
BINGHAM McHALE LLP  
2700 Market Tower  
10 W. Market Street  
Indianapolis, Indiana 46204-4900  
Phone: (317) 635-8900  
Fax: (317) 236-9907  
dtittle@binghammchale.com  
khidde@binghammchale.com

OF COUNSEL:

Daryl L. Wiesen  
Emily L. Rapalino  
GOODWIN PROCTER LLP  
53 State Street  
Boston, MA 02109  
Tel: (617) 570-1000  
dwiesen@goodwinprocter.com  
erapalino@goodwinprocter.com

Michael B. Cottler  
Jonathan E. Grossman  
Eric H. Yecies  
GOODWIN PROCTER LLP  
620 Eighth Avenue  
New York, NY 10018  
Tel: (212) 813-8800  
mcottler@goodwinprocter.com  
jgrossman@goodwinprocter.com  
eyecies@goodwinprocter.com

*Attorneys for Defendants Teva Parenteral  
Medicines, Inc., APP Pharmaceuticals, LLC,  
Pliva Hrvatska d.o.o., Teva Pharmaceuticals  
USA, Inc. and Barr Laboratories, Inc.*

INDS02 JMC 1216665v1